NO20072665L - Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser - Google Patents

Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser

Info

Publication number: NO20072665L
Authority: NO; Norway
Prior art keywords: neurological disorders; treatment; rapamycin derivatives; compounds; rapamycin
Prior art date: 2004-12-20

Application number

NO20072665A

Other languages

English (en)

Norwegian (no)

Inventor

Kevin Pong

Edmund Idris Graziani

Jerauld Skotnicki

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-20

Filing date

2007-05-25

Publication date

2007-09-07

2007-05-25 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-09-07 Publication of NO20072665L publication Critical patent/NO20072665L/no

Links

208000012902 Nervous system disease Diseases 0.000 title abstract 3
208000025966 Neurological disease Diseases 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
206010019196 Head injury Diseases 0.000 abstract 1
230000000626 neurodegenerative effect Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)

NO20072665A 2004-12-20 2007-05-25 Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser NO20072665L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63800404P	2004-12-20	2004-12-20
PCT/US2005/045331 WO2006068905A2 (en)	2004-12-20	2005-12-15	Rapamycin derivatives and the uses thereof in the treatment of neurological disorders

Publications (1)

Publication Number	Publication Date
NO20072665L true NO20072665L (no)	2007-09-07

Family

ID=36602218

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072665A NO20072665L (no)	2004-12-20	2007-05-25	Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser

Country Status (16)

Country	Link
US (3)	US7273874B2 (es)
EP (1)	EP1828203A2 (es)
JP (1)	JP2008524232A (es)
KR (1)	KR20070090931A (es)
CN (1)	CN101084226A (es)
AU (1)	AU2005319427B2 (es)
BR (1)	BRPI0519593A2 (es)
CA (1)	CA2590254A1 (es)
CR (1)	CR9149A (es)
IL (1)	IL183772A0 (es)
MX (1)	MX2007007409A (es)
NI (1)	NI200700156A (es)
NO (1)	NO20072665L (es)
RU (1)	RU2007119585A (es)
WO (1)	WO2006068905A2 (es)
ZA (1)	ZA200705123B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR040693A1 (es)	2002-07-30	2005-04-13	Wyeth Corp	Formulaciones parenterales
CA2556622A1 (en) *	2004-03-02	2005-09-15	Wyeth	Macrolides and methods for producing same
MXPA06014080A (es) *	2004-06-03	2007-02-15	Wyeth Corp	Agregado de genes biosinteticos para la produccion de un policetido complejo.
RU2007119585A (ru) *	2004-12-20	2009-01-27	Вайет (Us)	Производные рапамицина и их применение при лечении неврологических заболеваний
NZ574663A (en) *	2004-12-20	2010-05-28	Wyeth Corp	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
EP1859274A2 (en) *	2005-03-07	2007-11-28	Novartis AG	Genes involved in neurodegenerative conditions
WO2007067566A2 (en) *	2005-12-07	2007-06-14	Wyeth	Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
CN101321770A (zh) *	2005-12-07	2008-12-10	惠氏公司	由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法
AR058282A1 (es) *	2005-12-07	2008-01-30	Wyeth Corp	Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR059738A1 (es) *	2006-03-07	2008-04-23	Wyeth Corp	Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos
TW200824713A (en) *	2006-10-18	2008-06-16	Wyeth Corp	Processes for the synthesis of individual isomers of mono-PEG CCI-779
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US20100196355A1 (en) *	2007-01-29	2010-08-05	Wyeth	Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
MX2010003371A (es)	2007-09-28	2010-05-05	Intrexon Corp	Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
WO2009105510A1 (en) *	2008-02-19	2009-08-27	Wyeth	Methods for using rapamycin analogues in the treatment of neurological disorders
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
KR20130010121A (ko)	2010-03-23	2013-01-25	인트렉손 코포레이션	치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
ES2372077B2 (es) *	2010-06-24	2012-05-18	Universidad De Sevilla	Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
JP6189754B2 (ja)	2011-03-04	2017-08-30	イントレキソンコーポレーション	タンパク質を条件的に発現するベクター
CN102274219A (zh) *	2011-06-27	2011-12-14	苏州大学附属第一医院	雷帕霉素在治疗蛛网膜下腔出血早期脑损伤的应用
WO2014059295A1 (en)	2012-10-12	2014-04-17	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
US9121859B2 (en) *	2012-12-04	2015-09-01	Siemens Healthcare Diagnostics Inc.	Compounds and methods for determination of FKBP-binding immunosuppressant drugs
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
EP3089737B1 (en)	2013-12-31	2021-11-03	Rapamycin Holdings, LLC	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
UY37343A (es)	2016-07-25	2018-02-28	Intrexon Corp	Control del fenotipo en plantas
WO2018089527A1 (en)	2016-11-09	2018-05-17	Intrexon Corporation	Frataxin expression constructs
US20210154372A1 (en)	2017-05-15	2021-05-27	C.R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
WO2019157382A1 (en) *	2018-02-09	2019-08-15	Mount Tam Therapeutics, Inc.	Rapamycin analog for prevention and/or treatment of neurodegenerative conditions
WO2019157374A1 (en) *	2018-02-09	2019-08-15	Mount Tam Therapeutics, Inc.	Rapamycin analog for prevention and/or treatment of neurodegenerative conditions
EP3880266B1 (en)	2018-11-14	2025-05-07	Lutonix, Inc.	Medical device with drug-eluting coating on modified device surface
EP3952937A1 (en)	2019-04-08	2022-02-16	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
TW202206093A (zh) *	2020-08-12	2022-02-16	中國醫藥大學	Ｓｅｍａ３ｄ拮抗劑用於預防或治療神經退化性疾病以及延長壽命之用途
US20240376122A1 (en) *	2021-06-25	2024-11-14	Apertor Pharmaceuticals, Inc.	Small molecule compounds
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1445742A1 (de)	1963-11-06	1968-12-19	Bayer Ag	Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de)	1965-06-21	1969-12-11	Bayer Ag	Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
CA930734A (en)	1969-08-11	1973-07-24	Bickel Hans	Antibiotically active rifamycin compounds and processes for their manufacture
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en)	1973-04-05	1975-08-19	Lepetit Spa	3-formylrifamycin azines
US3905981A (en)	1973-10-12	1975-09-16	Research Corp	N-dealkylation of tertiary amines
US4127720A (en)	1977-09-21	1978-11-28	Bristol-Myers Company	Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja)	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
JPH05507915A (ja)	1990-06-11	1993-11-11	藤沢薬品工業株式会社	特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
DE4021404A1 (de)	1990-07-05	1992-01-09	Sandoz Ag	Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
GB2249027A (en)	1990-10-23	1992-04-29	Fujisawa Pharmaceutical Co	Use of macrolide compounds for hepatic failure
WO1992013862A1 (en)	1991-02-05	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Lactone compounds
US5604294A (en)	1991-09-05	1997-02-18	Luly; Jay R.	Macrocyclic immunomodulators
ES2179823T3 (es)	1991-09-05	2003-02-01	Abbott Lab	Inmunosupresor macrolido.
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
ES2295093T3 (es)	1993-04-23	2008-04-16	Wyeth	Conjugados y anticuerpos de rapamicina.
US7279561B1 (en)	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
US5798355A (en)	1995-06-07	1998-08-25	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity
US5525610A (en)	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
TW427904B (en)	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
US5717092A (en)	1996-03-29	1998-02-10	Vertex Pharmaceuticals Inc.	Compounds with improved multi-drug resistance activity
US5780484A (en)	1996-11-13	1998-07-14	Vertex Pharmaceuticals Incorporated	Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en)	1998-06-03	2001-02-13	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
EP1083872A1 (en)	1998-06-03	2001-03-21	GPI NIL Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US6015809A (en)	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
PT1105395E (pt)	1998-08-17	2002-09-30	Wyeth Corp	Rapamicinas fotociclizadas
WO2000034239A2 (en)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
WO2001018006A1 (en)	1999-09-09	2001-03-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6569867B2 (en)	1999-10-01	2003-05-27	Kosan Biosciences, Inc.	Polyketide derivatives
DE60033965T2 (de) *	1999-10-29	2008-01-10	Kosan Biosciences, Inc., Hayward	Rapamycin analoge
CA2407259A1 (en)	2000-05-17	2001-11-22	Chaitan Khosla	Polyketide derivatives
DK1419154T3 (da)	2001-08-22	2006-01-09	Wyeth Corp	Rapamycin-29-enoler
EP1419153A1 (en)	2001-08-22	2004-05-19	Wyeth	Rapamycin dialdehydes
CA2492153C (en)	2002-07-16	2012-05-08	Biotica Technology Limited	Production of polyketide fkbp-ligand analogues
NZ574663A (en) *	2004-12-20	2010-05-28	Wyeth Corp	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
RU2007119585A (ru) *	2004-12-20	2009-01-27	Вайет (Us)	Производные рапамицина и их применение при лечении неврологических заболеваний
AR059738A1 (es) *	2006-03-07	2008-04-23	Wyeth Corp	Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

2005
- 2005-12-15 RU RU2007119585/04A patent/RU2007119585A/ru not_active Application Discontinuation
- 2005-12-15 MX MX2007007409A patent/MX2007007409A/es active IP Right Grant
- 2005-12-15 AU AU2005319427A patent/AU2005319427B2/en not_active Ceased
- 2005-12-15 CN CNA2005800437050A patent/CN101084226A/zh active Pending
- 2005-12-15 KR KR1020077013852A patent/KR20070090931A/ko not_active Withdrawn
- 2005-12-15 EP EP05854115A patent/EP1828203A2/en not_active Withdrawn
- 2005-12-15 JP JP2007546876A patent/JP2008524232A/ja active Pending
- 2005-12-15 WO PCT/US2005/045331 patent/WO2006068905A2/en not_active Ceased
- 2005-12-15 CA CA002590254A patent/CA2590254A1/en not_active Abandoned
- 2005-12-15 US US11/300,941 patent/US7273874B2/en not_active Expired - Fee Related
- 2005-12-15 BR BRPI0519593-4A patent/BRPI0519593A2/pt not_active IP Right Cessation
2007
- 2007-05-24 CR CR9149A patent/CR9149A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072665A patent/NO20072665L/no not_active Application Discontinuation
- 2007-06-07 IL IL183772A patent/IL183772A0/en unknown
- 2007-06-18 NI NI200700156A patent/NI200700156A/es unknown
- 2007-06-19 ZA ZA200705123A patent/ZA200705123B/xx unknown
- 2007-08-14 US US11/891,879 patent/US7476678B2/en not_active Expired - Fee Related
2008
- 2008-12-05 US US12/329,106 patent/US20090088448A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2590254A1 (en)	2006-06-29
MX2007007409A (es)	2007-07-12
RU2007119585A (ru)	2009-01-27
US20060135550A1 (en)	2006-06-22
IL183772A0 (en)	2007-09-20
AU2005319427B2 (en)	2011-11-03
US20080027089A1 (en)	2008-01-31
US7476678B2 (en)	2009-01-13
US20090088448A1 (en)	2009-04-02
US7273874B2 (en)	2007-09-25
CN101084226A (zh)	2007-12-05
WO2006068905A3 (en)	2006-12-07
WO2006068905A2 (en)	2006-06-29
JP2008524232A (ja)	2008-07-10
EP1828203A2 (en)	2007-09-05
ZA200705123B (en)	2010-01-27
KR20070090931A (ko)	2007-09-06
CR9149A (es)	2007-10-23
BRPI0519593A2 (pt)	2009-02-25
AU2005319427A1 (en)	2006-06-29
NI200700156A (es)	2008-06-17

Legal Events

Date	Code	Title	Description
2010-07-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072665L (no)	2007-09-07	Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
NO20072664L (no)	2007-06-25	Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser
DK1543011T3 (da)	2006-08-07	Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
NO20081315L (no)	2008-05-15	Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20064929L (no)	2006-12-20	Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes
IL182218A0 (en)	2007-09-20	Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
NO20080475L (no)	2008-04-15	Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
NO20074959L (no)	2007-10-02	Substituerte pyridinderivater
NO20082096L (no)	2008-05-29	Azaindol-2-karboksamidderivativer
NO20082136L (no)	2008-06-30	1,5-substituerte indol-2-yl-amidderivater
WO2008002956A3 (en)	2008-07-03	Thiazoline and oxazoline derivatives and their methods of use
WO2008115999A8 (en)	2008-12-24	Biaryl and biheteroaryl compounds useful in treating iron disorders
WO2006110187A3 (en)	2007-04-26	Methods and compositions for the treatment of anxiety disorders
WO2007145835A3 (en)	2008-03-06	Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
EA200800081A1 (ru)	2008-06-30	Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
NO20081905L (no)	2008-06-23	Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
NO20083036L (no)	2008-09-05	Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
NO20083058L (no)	2008-10-09	Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
BR0316723A (pt)	2005-10-18	Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2005086656A3 (en)	2005-12-29	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EA200600071A1 (ru)	2006-08-25	Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
EA200870093A1 (ru)	2009-02-27	Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения
BRPI0506970A (pt)	2007-07-03	derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2002079169A8 (en)	2004-04-29	Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
NO20082214L (no)	2008-07-31	1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer